Studies, country | n | Disease duration Years | Age at visit Years | CRa % | Study design |
---|---|---|---|---|---|
Bertilsson, 2013 Sweden | 86 | 17 | n.a. | 40b | Prospective, population-based Diagnosis 1984-86 |
Selvaag, 2016 South-East Norway | 176 | 30 | 39 | 59c | Prospective, hospital-based Referral 1980-85 |
Oliveira-Ramos, 2016 Portugal | 426 | 23 | 34 | 12 | Cross-sectional, national register-based (“Reuma.pt register”), n = 355 retrospectively registered in adulthood |
Dimopoulou, 2017 Greece | 102 (302d) | 17 | 25 | 24 (47d) | Retrospective, hospital-based (n = 102) + telephone interview of n = 205 lost-to follow-up. N = 74 diagnosed before 2000 |
Minden, 2019 Germany | 701 | 14 | 23 | 11 | Prospective register-based (“BiKeR/JUMBO registry”), selected to bDMARDs-treated individuals |
Glerup, 2020 Nordic countries | 434 | 18 | 24 | 33 | Prospective, population-based (“Nordic JIA study”) Disease onset 1997–2000 |
Chhabra, 2020 Canada | 247 | 6 | 17 | 47 | Prospective, inception cohort (“ReACCH-Out cohort”) with retrospective long-term data collection. Diagnosis 2005–2020 |
Oliveira-Ramos, 2023 Portugal | 361 | 20 | 29 | 15 | Cross-sectional, national register-based (“Reuma.pt register”), selected to bDMARDs-treated individuals |